RIGL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RIGL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Rigel Pharmaceuticals's intangible assets for the quarter that ended in Dec. 2024 was $27.1 Mil.
The historical data trend for Rigel Pharmaceuticals's Intangible Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rigel Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Intangible Assets | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | 14.95 | 13.88 | 27.10 |
Rigel Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Intangible Assets | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
13.88 | 28.86 | 28.28 | 27.69 | 27.10 |
Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.
Rigel Pharmaceuticals (NAS:RIGL) Intangible Assets Explanation
If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.
The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.
Some intangibles are amortized. Amortization is the depreciation of intangible assets.
Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.
Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.
If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.
Intangibles acquired are on balance sheet at fair value.
Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.
One of the reasons competitive advantage power can remain hidden for so long.
Be Aware
Companies may change the way intangible assets are amortized, and this will affect their reported earnings.
Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Raymond J. Furey | officer: EVP, GC & Corp Sec | 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807 |
David A Santos | officer: EVP, Chief Commercial Officer | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080 |
Dean L Schorno | officer: EVP & Chief Financial Officer | 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
Raul R Rodriguez | officer: Sr VP of Bus Dev and Com Ops | 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Wolfgang Dummer | officer: EVP & CMO | 5491 OPTICAL CT., SAN JOSE CA 95138 |
Alison L. Hannah | director | 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913 |
Gary A Lyons | director | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
Anthony Gregg Lapointe | director | PO BOX 83216, GAITHERSBURG MD 20883-3216 |
Brian L. Kotzin | director | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94060 |
Kamil Ali-jackson | director | C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355 |
Jane Wasman | director | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Nelson Cabatuan | officer: Principal Accounting Officer | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080 |
Anne-marie Duliege | officer: Chief Medical Officer | 4001 MIRANDA AVENUE, PALO ALTO CA 94304 |
Mayer Eldon C. Iii | officer: EVP & Chief Commercial Officer | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080 |
Stacy Markel | officer: EVP Human Resources | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By GuruFocus News • 11-08-2024
By GuruFocus News • 03-05-2025
By PRNewswire • 01-09-2025
By GuruFocus News • 11-08-2024
By PRNewswire • 10-31-2024
By PRNewswire • 02-25-2025
By GuruFocus News • 03-05-2025
By GuruFocus News • 02-07-2025
By PRNewswire • 11-12-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.